Van Eck Associates Corp Zai Lab LTD Transaction History

Van Eck Associates Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$22.72 - $31.49 $4,589 - $6,360	202 Added 146.38%	340 $8,000
Q1 2023 May 03, 2023	SELL	$30.21 - $48.1 $120 - $192	-4 Reduced 2.82%	138 $5,000
Q4 2022 Feb 08, 2023	BUY	$22.28 - $38.71 $1,314 - $2,283	59 Added 71.08%	142 $4,000
Q3 2022 Oct 27, 2022	BUY	$34.2 - $51.69 $1,299 - $1,964	38 Added 84.44%	83 $3,000
Q2 2022 Aug 03, 2022	BUY	$23.14 - $49.68 $347 - $745	15 Added 50.0%	45 $2,000
Q4 2021 Jan 26, 2022	SELL	$54.9 - $105.21 $6.06 Million - $11.6 Million	-110,455 Reduced 99.97%	30 $2,000
Q3 2021 Nov 03, 2021	SELL	$105.0 - $178.37 $6.97 Million - $11.8 Million	-66,350 Reduced 37.52%	110,485 $11.6 Million
Q2 2021 Aug 10, 2021	BUY	$125.11 - $180.0 $22.1 Million - $31.8 Million	176,815 Added 884075.0%	176,835 $31.3 Million
Q1 2021 May 13, 2021	BUY	$126.27 - $191.71 $2,525 - $3,834	20 New	20 $3,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.52B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.